Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Abstract

Background This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma. Methods Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined. Results Among 485 patients, 171 were positive for mesothelin, 368 were positive for CA125, and 167 were positive for mesothelin and CA125. The expression of mesothelin and CA125 was positively correlated (p < 0.01). More patients with mesothelin expression showed myometrial invasion of more than 50% (p = 0.028) and positive lymphovascular invasion (p = 0.027). Similarly, more patients with co-expression of mesothelin and CA125 had myometrial invasion of more than 50% (p = 0.016) and positive lymphovascular invasion (p = 0.02). Patients with mesothelin expression and co-expression of mesothelin and CA125 demonstrated worse progression-free survival (PFS) and overall survival (OS). In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression: hazard ratio [HR] = 2.14, p < 0.01; co-expression: HR = 2.19, p < 0.01) and OS (mesothelin expression: HR = 2.18, p < 0.01; co-expression: HR = 2.22, p < 0.01). Conclusions Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.

Preoperative Prediction Value of Pelvic Lymph Node Metastasis of Endometrial Cancer: Combining of ADC Value and Radiomics Features of the Primary Lesion and Clinical Parameters

“…In clinical practice, CA125 has been routinely used to diagnose a variety of malignancies, especially epithelial ovarian cancer [ 28 ]. Quan et al [ 29 ] demonstrated that serum CA125 significantly correlated with clinicopathological risk factors, such as depth of myometrial invasion, LN status, and FIGO stage and that CA125 is a promising prognostic indicator for EC [ 30 , 31 ]. In our study, CA125 could be used as an independent predictor of PLNM in EC patients, which is consistent with the results of Lei et al [ 32 ].…”

NAV‐003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors

“…MSLN-positive cancers are well known to co-express immunosuppressive HIO factors. Cancers expressing high MSLN levels such as malignant pleural mesothelioma, nonmucinous ovarian, endometrial, and pancreatic adenocarcinoma have all been documented to express the immunosuppressive MUC16/CA125 [26][27][28] as well as MUC1 [29][30][31][32]. Antibody-based therapies that employ ADCC and CDC immune effector activities have had modest efficacy in treating these diseases and only few studies have correlated HIO factor levels with preclinical or clinical outcomes.…”

Preoperative serum CA125 level is a good prognostic predictor in patients with intrahepatic cholangiocarcinoma after hepatectomy: A single-center retrospective study

“…Previous studies have confirmed that serum CA125 is a predictor of prognosis in various malignancies, including epithelial ovarian cancer, [7] cervical adenocarcinoma, [9] and endometrial carcinoma. [13] CA125 is a transmembrane mucin encoded by the mucin 16 (MUC16) gene. [14] CA125/MUC16 might also play an important role in the tumorigenesis and metastasis of pancreatic cancer [15] and ovarian tumors.…”